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Abstract.  Lymphocyte attachment to fibronectin is 
mainly mediated by the interaction of ix5/31 and ot4/31 
integrins  with the RGD and CS-1/Hep II sites, respec- 
tively. We have recently shown that the anti-/31 mAb 
TS2/16 can convert the partly active a4B1 present on 
certain hemopoietic cells that recognizes CS-1 but not 
Hep II, to a high avidity form that binds both ligands. 
In this report we have studied whether mAb TS2/16 
also affects ot4B1 ligand specificity. Incubation of the 
B cell lines Ramos and Daudi (which lack ix5/31) with 
mAb TS2/16 induced specific attachment to an 80-kD 
fragment which lacks CS-1  and Hep II and contains 
the RGD sequence,  mAbs anti-oM and the synthetic 
peptides CS-1  and IDAPS inhibited adhesion to the 
80-kD fragment thus implying ol4/31 as the receptor 
for this fragment.  Interestingly,  the synthetic peptide 
GRGDSPC and a  15-kD peptic fibronectin fragment 
containing the RGD sequence also inhibited B cell 
adhesion to the 80-kD fragment.  Because we have 
previously shown that RGD peptides do not affect the 
constitutive function of ot4/31, we tested whether 
TS2/16-aetivated o~4/31 acquired the capacity to recog- 
nize RGD. Indeed RGD peptides inhibited TS2/16- 
treated B cell adhesion to a  38-kD fragment containing 
CS-1  and Hep II but did not affect binding of un- 
treated ceils to this fragment.  An anti-fibronectin mAb 
reactive with an epitope on or near the RGD sequence 
also efficiently inhibited cell adhesion to the 80-kD 
fragment,  indicating that the RGD sequence is a novel 
adhesive ligand for activated ot4/31. These results em- 
phasize the role of ot4/31 as a receptor with different 
ligand specificities according to the activation state, a 
fact that may be important  for lymphocyte migration, 
localization,  and function. 
YMPHOCYTE interactions  with fibronectin  (Fn) l are im- 
portant  for their  differentiation,  migration,  activa- 
tion,  and biological function  (reviewed  in 20,  46). 
The specific sequences in Fn that mediate cell attachment are 
located within two main regions of the molecule: the central 
cell-binding domain contains the RGD site which acts in syn- 
ergy with at least two other regions within this domain (56). 
The carboxy-terminal  region of Fn comprises the Hep II do- 
main and the IIICS region. Within the Hep II domain the fol- 
lowing  sites  have  been  shown  to  support melanoma  cell 
adhesion:  HI (35),  FNC/H I, and FNC/H II (21, 31). Two 
active sites have been identified within IIICS,  namely CS-1 
(residues 1-25) and CS-5 (residues 90-109) (19). Both CS-1 
and CS-5 are regulated by alternative  splicing  and are not 
present in all Fn isoforms.  While CS-1 and the entire Hep 
II domain clearly mediate lymphocyte adhesion to Fn (15, 
16, 52) it is not known if these cells recognize  the specific 
sequences contained in H1, FNC/H I, FNC/H II, and CS-5. 
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Lymphocytes interact with Fn mainly via two main receptors 
which belong to the integrin family: the ot5/31 integrin is the 
receptor for the RGD and synergistic  sites (42).  The c~4/31 
integrin  is the receptor for H1 (35),  Hep II, and CS-1 (16, 
18, 33, 52) and CS-5 (34). 
The functional  activity of most integrins  can be regulated 
intracellularly  by phorbol esters (45, 54) or by the cytoplas- 
mic domain of some ot and/3 chains  (22, 39) as well as ex- 
tracellularly.  Among  these  external  factors  certain  l'nAb 
directed to the/3 subunit have been shown to upregulate the 
function of most 131,/32, and/33  integrins  (reviewed in 20). 
These mAb most likely induce a conformational  change on 
the  receptor  which  increases  the  affinity/avidity  for  its 
ligands.  Indeed, we and others have been able to measure 
this increase in the affinity of ct5B  1 for an 80-kD Fn fragment 
containing  the RGD sequence (2) or for intact Fn (11). The 
high  avidity  state can also be induced on solubilized  inte- 
grins and thus acquisition of the activated form is an intrinsic 
property of the receptor (2, 6, 38). The existence of low and 
high affinity interactions  with the extracellular  matrix may 
play a crucial role for the migration  and localization  of lym- 
phocytes. 
Using one of these activating  anti-/31 mAb (TS2/16),  we 
have recently shown that the ct4B1 integrin also exist on sev- 
eral states  of activation  among  different  hemopoietic ceils 
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cells, was able to bind two fragments of 38 kD (contains 
CS-1 and Hep II) (13) and 58 kD (contains Hep II) (15-17) 
derived from the A and B chains of  Fn, respectively. The less 
active form, present on monocytic cells and peripheral blood 
T  lymphocytes, bound only the 38-kD  fragment and thus 
recognized CS-1 but not Hep II. mAb TS2/16 converted this 
a4~1 form to a more active one able to recognize both sites. 
These previous observations therefore indicate that there are 
cell populations which constitutively express a low or inter- 
mediate avidity a4/$1 form unable to recognize some of its 
ligands. In view of these results it was conceivable that acti- 
vation of the receptor would lead to the recognition of new 
low affinity ligands not previously identified. 
In the present report we have studied whether ot4/~1 activa- 
tion via the/31  subunlt affects the ligand specificity of this 
receptor. We show that o~5/~l-negative  B lymphoid cells that 
do  not  bind  constitutively  to  the  80-kD  Fn  fragment, 
efficiently  attach to this fragment upon incubation with mAb 
TS2/16. We have identified the t~4/$1 integrin as the receptor 
that mediates adhesion to the 80-kD fragment and we show 
that the RGD sequence in Fn is a novel ligand for activated 
.4~1. 
Materials and Methods 
ECM Proteins, Fragments, and Synthetic Peptides 
Human plasma Fn was the generous gi~ of Drs. B. Horowitz and R. Shulman 
(New York Blood Center,  New York). Fragments of 80, 58, 38, 31, and 29 
kD (see Fig. 1) were obtained from tryptic digestions of Fn and purified ex- 
actiy as previously described (13-15). Purity of the 80-kD fragment was as- 
sessed by SDS-PAGE,  Western blots, ELISA,  and NH2-terminal  amino 
acid sequencing.  Amino acid sequence  analyses  were performed by Mr. 
Javier Varela at the Protein Chemistry Laboratory,  Centro de Investiga- 
ciones Biol6gicas  (Madrid, Spain),  using a 477A liquid-phase sequencer 
(Applied  Biosystems,  Inc.,  Foster City,  CA).  The 80-kD fragment was 
cleaved  with pepsin (1:100 wt/wt,  37"C,  1 h) as described (40).  Peptic 
digests  were resolved  by fast protein liquid chromatography (Pharmacia 
LKB  Biotechnology,  Uppsala,  Sweden)  using a  Mono Q  ion exchange 
column (Phannacia LKB Biotechnology)  equilibrated in 10 mM Tris pH 
7.0, buffer (A). Bound fragments were eluted by applying a 45-min gradient 
from 100% A to 40% A-60% B (10 mM Tris,  500 mM NaC1, pH 7.0). 
Characterization of peptic fragments was achieved by SDS-PAGE, Western 
blots, ELISA,  and NH2-terminal  amino acid sequencing.  Purified  frag- 
ments were dialyzed versus PBS and stored at -70°C. The following syn- 
thetic peptides were purchased from Bio-Synthesis  D&I (Madrid, Spain): 
GRGDSPC and GRGES, containing sequences from the central cell-binding 
domain;  DELPQLVTLPHPNLHGPEILDVPSTC  (CS-1), PSTVQKTPF- 
VTHPGYDTGNGIQLPG  (CS-2),  and,  CIQLPGTSGQQPSVGQQMIF- 
EEHGFR (CS-3), containing sequences from the I]ICS region, and IDAPS 
containing an active sequence present in the Hep II domain (35). Laminin 
and collagen  type  I  were  purchased  from  Sigma Chemical Co.  (Saint 
Louis,  MO). 
Monoclonal Antibodies 
Fn-specific  mAbs P1Fll (anti-CS-1) and P3D4 (anti-Hep II domain) were 
produced as reported (17). mAbs N-295 and N-296 were originally pur- 
chased from Mallinckrodt Specialty  Chemicals (Maryland Heights,  MO) 
and are now available through Chemic.on International, Inc. (MABI934 and 
MAB1935, respectively;  Temecula, CA). mAb N-295 reacts with the 11-kD 
fragment  that contains the RGD sequence of fibronectin (40) and partially 
inhibits cell adhesion (32). mAb N-296 reacts with a carboxy-terminal frag- 
ment that contains the Fib II domain and does not affect cell adhesion (32). 
mAbs to the ct4 integrin subtmit HP1/1 (epitope A), HP2/1  (epitope B1), 
and mAbs Alex 1/4 and TS2/16 specific for the/51  subunit were obtained 
from Dr.  E  S(mchez-Madrid  (Hospital de la Princesa,  Madrid,  Spain). 
mAbs P1D6 (anti-a5) and P1B5 (anti-c~3) were obtained from Dr.  E. A. 
Wayner (University of Minnesota, Minneapolis, MN). mAb LM609 (anti- 
tAr~3) was obtained from Dr. D. Cheresh (Scripps Clinic, San Diego, CA). 
mAb IIF5 (anti-a3) was obtained from Dr. M. Hemier (Dana Farber Can- 
cer Institute, Boston, MA). mAb D3/9 (anti-CD45)  was obtained from Dr. 
C. Bernabeu (Centro de Investigaciones  Bitlogicas, Madrid, Spain). 
Cells and Cell Culture 
The human cell lines Daudi, RPM18866, JY (B lymphoblastoid), and K562 
(erythroleukemia)  were obtained from Drs. E Sfmchez-Madrid and C. Ber- 
nabeu. The melanoma cell line A375  was obtained from Dr.  J.  Teixid6 
(Centro de Investigaciones  Biol6gicas).  The B cell line Ramos  and the 
monocytic cell line U937 were obtained from the American Type Culture 
Collection (Rackville,  MD).  Cells were expanded in RPMI  1640,  sup- 
plemented with 10% hot-inactivated fetal bovine serum (Gibco,  Middle- 
sex, UK), 2 mM L-glutamine,  100 U/ml penicillin (Antibi6ticos,  Madrid, 
Spain),  and 24 #f/nil gentamycin (Llorente,  Madrid, Spain).  In general, 
three/four-day  cultures were used for assays. 
Cell Attachment Assays 
These assays were performed exactly as described (44) using flat bottom, 
high binding, 96-well plates (Costar Corp., Cambridge, MA). Quantitation 
of cell attachment was done by determining the absorbance at 620 um on 
a Multiskan Bichromatic plate reader (Labsystems,  Helsinki, Finland) and 
using calibration curves as described (44). Integrin activation through the 
/31 subunit was performed by incubating the cells with a I:10 dilution of su- 
pernatant containing anti-/~l rnAbs for 15-20 rain at 37°C prior to the at- 
tachment assay. For inhibition experiments cells were incubated with anti- 
integrin antibodies (15 rain, 37°C)  or synthetic peptides or fragments (30 
rain, room temperature) prior to adding to substrate-coated  wells. Inhibi- 
tion of cellular attachment  by antibodies to Fn was determined after incuba- 
tion of 80- or 38-kD-coated wells with 50 #1 of appropriate antibody dilu- 
tions for 30 rain at room temperature; 50 #1 of cell suspension was then 
added and the assay continued as described above. 
Immunofluorescence  Analyses 
Cells (5  ×  105) were incubated for 30 min at 4"C with 100 #1 of culture 
superuatants (1:2 dilution) or ascites (1:500 dilution) containing the appro- 
pilate  mAb.  Cells  were  washed  twice  with  cold  PBS-I%  BSA  and 
resuspended in 100 #1 of a 1/100 dilution of fluorescein-conjugated  F(ab')2 
fragments of rabbit antibodies to mouse IgG (Dakopatts,  Glostrop,  Den- 
mark). After 30 min at 4°C cells were washed twice,  resuspended in PBS, 
and analyzed by flow cytometry on an EPICS-CS  (Coulter Cientifica, 
Mdstoles, Spain). 
ELISA Assays 
These  assays  were  performed  as  described  (17) with  the  following 
modifications  to improve background: Fn fragments used for coating wells 
were in 0.1 M sodium borate, pH 8.5 (instead of PBS); plates were washed 
with 0.1% Tween 20 (instead  of 0.05%);  incubation with antibodies was 
done at room temperature (instead of 37°C).  Absorbance at 492 um was 
determined after 10 and 30 rain using a microplate reader. 
Results 
Fibronectin Fragments That Contain 
the Central (RGD-dependent) or Carboxy-terminal 
(RGD-independent) Cell-binding Domains 
The Fn tryptic fragments of 38 and 80 kD used in the pres- 
ent study have been previously characterized and are sche- 
matically shown in Fig.  1.  The 38-kD  fragment, derived 
from the carboxy-terminal region of the A chain of Fn, con- 
rains the Hep II domain and part of the [LICS region includ- 
ing the CS-1 site (13, 15, 17). The 80-kD fragment, derived 
from the central region of both chains of Fn, contains a low- 
affinity  heparin and DNA-binding domain, the RGD sequence 
and the RGD-dependent synergistic sites (56).  Both frag- 
ments are contiguous in the Fn sequence. 
The Journal of Cell Biology, Volume 126, 1994  272 DNNHep  ==  •  Cell  =.  s,. 
Z.__\  /____\  I 
Synergy sites  RGDS 
•  ~  40/45 kD  m.  .,,~--~ 5 kD 
80 kD 
(both  chains) 
38 kD  (A chain) 
Figure 1. Schematic drawing of the 38- and 80-kD Fn tryptic frag- 
ments used in this study. Fibronectin type lII homology repeats con- 
tained in these fragments are indicated and numbered. The 80-kD 
fragment contains  a  DNA/hepaxin-binding  domain  and  a  cell- 
binding domain composed of  the RGD sequence and the synergistic 
regions. The location of the peptic fragments 40/45 and 15 kD is 
indicated. The 38-kD fragment is derived from the A chain of Fn 
and contains the HeplI domain and part of the I]/CS region.  The 
location of the active sites within these regions is indicated.  The 
CS-5 site (see Introduction) is not contained in the 38-kD fragment. 
Both fragments are contiguous in the Fn sequence. 
Analysis  of the  80-kD  fragment rendered  the  NH2-ter- 
fiainal  sequence  SDVPTS.  Further  characterization  of this 
fragment was achieved using two recently developed mAbs 
with  specificity  for the  Hep  II (P3IM)  and  CS-1  (P1Fll) 
regions,  respectively  (17)  as  well  as  a  commercial  mAb 
(N-295) which reacts with a site near the RGD sequence in 
Fn (32).  As shown in Fig.  2,  using an ELISA assay, mAb 
N-295  reacted  strongly  with  the  80-kD  fragment  while 
mAbs P3D4 and P1F11 were negative. These two mAbs also 
failed to  recognize  the  80-kD  fragment on Western  blots 
(17).  mAbs P3D4 and P1Fll did react with the 38-kD frag- 
ment used as control while mAb N-295 did not (Fig. 2). Al- 
together these results clearly show that the 80-kD fragment 
contains the RGD sequence and that there are no contami- 
nants containing  the ct4/31 ligands  Hep II and CS-1  in the 
80-kD fragment preparation. 
Pepsin digestion of the 80-kD fragment rendered two frag- 
ments of interest (Fig. 1): a 15-kD fragment that was positive 
on Western blots and ELISA with mAb N-295 (not shown) 
and thus contained the RGD sequence. The 15-kD fragment 
had  the  NH2-terminal  sequence:  IGQQ  (end  of  repeat 
111-9);  a  40/45-kD  fragment that rendered two sequences: 
VLV(R)WTPP (beginning at residue 18 in repeat II1-5) and 
IQVLRDGQ (end of repeat III-6). The 40/45-kD fragment 
did not react with mAb N-295 (not shown) and thus did not 
contain the RGD sequence. 
Adhesion of a5f31-negative  B Cell Lines 
to the 80-kD Fn Fragment Following Incubation 
with Anti-~l mAb TS2/16 
The following experiments were undertaken to  determine 
whether  mAb  TS2/16  affects not  only  the  affinity  of the 
receptor(s) but also its specificity thus resulting in the recog- 
nition of novel ligands. To this purpose we performed attach- 
ment assays using several Fn fragments not previously shown 
to support B lymphoid cell adhesion. These include the 80- 
kD fragment shown in Fig.  1 and two fragments of 29 and 
31 kD derived from the amino- and carboxy-terminal regions 
of Fn,  respectively (not shown in Fig.  1).  The various cell 
populations used in these studies and their pattern of integrin 
expression are listed in Table I. As can be observed none of 
the four B cell lines studied expressed the ct5 integrin subunit 
on their surface in agreement with previous reports (5,  16, 
47). As shown in Fig. 3, resting Ramos or Daudi cells or cells 
incubated with the control anti-~  mAb Alexl/4 did not at- 
tach  to  the  80-kD  fragment.  However,  preincubation  of 
Ramos or Daudi cells with mAb TS2/16 resulted in a dose- 
response attachment to the 80-kD fragment (Fig. 3). Incuba- 
tion of Ramos cells with mAb TS2/16 always resulted in a 
more efficient adhesion (60%) to the 80-kD fragment than 
incubation of Daudi cells (40%), a result consistent with the 
higher/~1 expression on Ramos cells (Table I). The surface 
expression of/~1  integrins  did  not  change upon treatment 
with mAb TS2/16  (1, 2,  and this report, not shown),  mAb 
TS2/16 did not induce binding of Ramos or Daudi cells to 
Figure 2. ELISA analysis of the reactivity ofmAb P1Fll  (anti-CS- 
1), P3D4 (anti-Hepll),  and N-295 (anti-RGD) with purified 80- and 
38-kD Fn fragments. Wells were coated with 80 (4/~g) or 38 kD 
(2  /zg) overnight  and  incubated  with  mAb PIF11 (no dilution), 
P3D4 (1:5 dilution), or N-295 (1:250 dilution). Quantitation of the 
reaction was done by measuring the absorbance at 492 nm. All de- 
terminations  were done in duplicates. 
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Figure 3. Adhesion of Ramos (A) and Daudi (B) B lymphoid cells 
to the 80-kD fragment.  Cells were preincubated with either mAb 
Alexl/4 (closed circles) or mAb TS2/16 (open circles) and added 
to wells coated with the indicated concentrations  of 80-kD frag- 
ment (5  x  104 cells/well).  After 30 min at 37°C, attached  cells 
were stained with 0.1% toluidine blue and quantitated as described 
in Materials and Methods. Each determination was done in dupli- 
cate and values represent the average of  three different experiments. 
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Lines Studied 
Mean fluorescence intensity 
Ceils  Control  c~2  ct3  a4  c~5  aVfl3  /~1 
Ramos  35  35  45  95  35  36  113 
Daudi  40  ND  39  96  40  43  76 
JY  49  48  47  103  46  71  51 
RPMI 8866  43  43  42  107  41  61  50 
K562  47  ND  45  46  78  56  100 
A375  43  89  82  80  68  102  123 
the  29-  or  31-kD  fragments  at  any  of the  concentrations 
tested (not shown). 
To confirm the specificity of the effect ofmAb TS2/16 and 
the involvement of/$1 integrins on the recognition of the 80- 
kD fragment, we studied the adhesion of the B cell lines JY 
and RPMI 8866 to this fragment. These cells were chosen 
because they do not express surface/$1 integrin subunit (Ta- 
ble I and reference 5, 47, 48).  Instead JY and RPMI 8866 
cells express an alternative/$ chain called 157, which is as- 
sociated with the or4 subunit (5,  41).  As shown in Fig. 4, 
mAb TS2/16 did not induce adhesion of JY or RPMI 8866 
cells to the 80-kD fragment. JY cells constitutively attached 
to the 80-kD fragment and mAb TS2/16  did not affect this 
constitutive binding (Fig.  4). 
Effect of  PMA on Adhesion of  B Cells to the 80-kD 
Fragment: Involvement of Two Different Receptors 
To  determine  whether  phorbol  myristate  acetate  (PMA) 
could reproduce the effect  of mAb TS2/16,  cells  were in- 
cubated with 50 ng/ml of PMA for 20 min and tested for 
adhesion to 80-kD coated wells.  As shown in Fig. 4, PMA 
did not induce attachment of either Ramos or Daudi cells to 
the  80-kD fragment while  on the  same experiment mAb 
TS2/16 was an effective inducer (Fig. 4). PMA did not affect 
either the constitutive adhesion of these ceils to the 38-kD 
fragment (not shown). In contrast to these results,  PMA was 
an effective activator of JY and RPMI 8866 cells.  As shown 
in Fig. 4,  PMA induced de novo adhesion of RPMI 8866 
cells to the 80-kD fragment and increased the constitutive 
binding of JY cells to this fragment. No changes on integrin 
surface expression were detected after PMA treatment (not 
shown). 
These results suggested the involvement of two different B 
cell receptors for the 80-kD fragment, one of them being 
regulated by mAb TS2/16 and the other by PMA. It was re- 
cently demonstrated that the otV/$3 integrin functions as a 
Fn receptor on some B lymphoid cells  (48).  To establish 
whether oN/$3 was the receptor for the 80-kD fragment on 
JY and RPMI 8866 cells, we performed attachment assays 
to this fragment in the presence of anti-oN/s3  mAb LM609. 
In  results  not  shown,  mAb LM609  completely  inhibited 
(100%) the adhesion of resting JY and PMA-treated RPMI 
8866 cells to the 80-kD fragment,  and partially  inhibited 
(45%) the attachment of PMA-treated JY cells to this frag- 
ment.  These  results  therefore confirm the involvement of 
aV/$3 on adhesion of/$1-negative B cells to the 80-kD frag- 
ment and suggest a role for yet another nonidentified recep- 
tor on PMA-stimulated JY cells, mAb LM609 had no effect 
on the adhesion of Ramos or Daudi cells to the 80-kD frag- 
ment (Fig.  5) in agreement with the lack of expression of 
oW/$3 on these cells (Table  I). 
Identification of the ~4~31 Integrin as a New Receptor 
for the 80-kD Fragment 
The preceding results clearly indicate that adhesion of Ra- 
mos and  Daudi  cells  to the  80-kD fragment is  regulated 
through the/31 subunit. To identify the receptor involved in 
adhesion to this fragment, cell attachment assays were car- 
ried out in the presence of several anti-integrin mAbs. As 
shown in Fig.  5, two anti-a4 mAbs, HP2/1  and HP1/1, in- 
hibited  TS2/16-treated  Ramos  (and TS2/16-treated Daudi, 
not shown) cell adhesion to the 80-kD fragment, mAbs P1D6 
Figure 4. Effect of PMA and mAb TS2/16 on the attachment of sev- 
eral B cell lines to the 80-kD fragment. Cells were incubated with 
either cell culture medium (resting), PMA (50 ng/ml), or mAb 
TS2/16 (1:10  dilution of supernatant) for 15 min at 37°C and added 
to 80-kD coated wells (38/~g/ml,  5  x  104 cells/well). After 30 
min at 37°C, attached cells were quantitated as described. Values 
are the average of three different experiments. 
Figure 5. Effect of several anti-integrin or control mAb on attach- 
ment of TS2/16-treated Ramos cells to the 80-kD fragment. Cells 
were incubated with mAb TS2/16 (15 min at 37°C) followed  by in- 
cubation with the indicated mAb for another 15 min. The dilutions 
used were 1:10 for mAb used as culture supernatants (D3/9, PID6, 
HP2/1, and HP1/1) and 1:500 for those used as ascitic fluid (IIF5 
and LM609).  Cells (5  x  104/well) were added to 80-kD coated 
wells (38 #g/ml) and after 30 min at 37°C, attached cells were 
quantitated as described. Values on the ordinate represent the per- 
centage of attached ceils relative to the number of cells on control 
wells (TS2/16, no inhibitor). Values are the means of two different 
experiments. 
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Figure 6. Inhibition of Ramos cell attachment to the 80-kD frag- 
ment by synthetic peptides. Ceils were incubated with mAb TS2/16 
15 min at 37°C followed  by 30-min incubation at room temperature 
with  the  indicated  dilutions  of synthetic peptides.  Ceils  (5  × 
104/well) were added to 80-kD coated wells (19 #g/well) and at- 
tached ceils were quantitated after 30 min at 37°C. Values on the 
ordinate are expressed as percentage of attached cells relative to the 
number of cells on control wells (TS2/16, no inhibitor). Values are 
the means of three different experiments. 
(anti-o~5), IIF5 (anti-or3),  LM609 (anti-oNB3), or the con- 
trol D3/9 (anti-CD45) had no effect on these assays (Fig. 5). 
The effect of the synthetic peptides CS-1  and IDAPS on 
TS2/16-treated Ramos cell adhesion to the 80-kD fragment 
was also tested. As shown in Fig. 6, CS-1 or IDAPS peptides 
produced a dose-dependent inhibition of cell attachment to 
the 80-kD fragment, while the control peptides CS-2 (Fig. 
6) and CS-3 (not shown) had no effect. Interestingly, the syn- 
thetic peptide GRGDSPC was also completely inhibitory in 
these assays while the control GRGES peptide had no effect 
(Fig.  6).  The calculated concentration (riM)  of peptide re- 
quired to produce 50 % inhibition of cell attachment to the 
80-kD fragment was 5.45 (CS-1,  15/~g/ml),  104 (GRGDS- 
PC,  80 #g/ml), and 400 (IDAPS, 220/zg/ml). Thus, CS-1 
was  the  most effective inhibitor and  the  RGD-containing 
peptide was a better inhibitor than the reported ot4/31 ligand 
IDAPS. 
The RGD Sequence is a Ligand for TS2/16-activated 
~4f31 Integrin 
The above results  therefore suggested that the  conforma- 
tional change induced in a4/31 by mAb TS2/16 results in the 
ability to recognize the RGD sequence. To prove this,  we 
tested the capacity of the GRGDSPC synthetic peptide to in- 
hibit the adhesion of resting and TS2/16-activated Ramos 
cells to the 38-kD fragment.  As  shown in Fig.  7,  resting 
Ramos cell adhesion to the 38-kD fragment was not affected 
(90%  specific  adhesion)  by  the  GRGDSPC  peptide  (0.5 
mg/ml) in agreement with our previous report (16). However 
upon incubation with mAb TS2/16, the GRGDSPC peptide 
(0.5 mg/ml) inhibited cell adhesion to the 38-kD fragment 
by 50% (Fig. 7). As expected, the CS-1 peptide used as con- 
trol was a good inhibitor in both cases. These results clearly 
show that soluble RGD-containing peptides can effectively 
Figure 7. Effect of the GRGDSPC synthetic peptide on Ramos cell 
attachment  to the  38-kD  fragment.  Ceils were either  untreated 
(Resting) or treated with mAb TS2/16 (15 rain, 37°C) and incubated 
30 min at room temperature with 0.5 mg/ml of GRGDSPC or CS-1 
peptides. Cells were added to wells coated with 0.8 ~g/ml (Resting) 
or 0.6 #g/ml (TS2/16  activated) of 38-kD fragment. The number of 
ceils on control wells (no inhibitor)  were 35.000 (Resting) and 
29.000 (TS2/16 treated). The number of attached ceils relative to 
control wells was quantitated as described. Values are the means 
of two different experiments. 
inhibit the function of activated o~4/$1 and that activated ot4/~l 
(but not resting o~4~1) acquires the capacity to recognize the 
RGD sequence. 
As shown in Table II, adhesion of TS2/16-treated Ramos 
cells to the 80-kD fragment was also inhibited by soluble 
80-, 38-, and 15-kD (RGD site) fragments. It was poorly in- 
hibited by the 40/45-kD fragment (no RGD). Direct binding 
to the 15-kD fragment however could not be demonstrated 
probably due to the low affinity displayed by this fragment 
when used as substrate. To further confirm that there was a 
specific ligand for ot4fll within the 80-kD fragment, we car- 
fled out cell attachment assays in the presence of a panel of 
anti-Fn mAbs. As shown in Fig. 8, mAb N-295 which recog- 
nizes an epitope near the RGD sequence, inhibited (80%) 
Ramos  cell  adhesion  to  the  80-kD  fragment while  mAb 
N-296 (anti-Fib 11) and P3IM (anti-Hep ID had no effect. 
These results together with the data shown in Fig. 7, indi- 
cate that ot4/~l interaction with the 80-kD fragment is pri- 
marily mediated by the RGD sequence. Because inhibition 
by mAb N-295 was not complete (Fig. 8), a small contribu- 
tion from other sites in the 80-kD fragment cannot be com- 
pletely ruled out. 
mAb TS2/16-induced Recognition of New Ligands May 
Be Specific for Fn and  for the ~4f31 Integrin 
We next tested whether mAb TS2/16 could induce the recog- 
Table II.  Effect of Fn Fragments on Adhesion of 
TS2/16-treated Ramos Cells to the 80-kD Fragment 
% Inhibition 
80 kD Coating concentration  80 kD  38 kD  15 kD  45 kD  31  kD 
tLg/ml  4.5*  3  4.5  1.8  3 
19  80  100  85  10  2 
38  70  100  50  0  0 
* Nanomoles of ~agments use,  din ~emcubafionmixmre. 
S~mchez-Aparicio et al. Activated et4~l Recognizes the RGD Fibronectin  Site  275 O 
O 
m 
w 
.$ 
t,J 
100;  -'-  -'-  --- 
80 
60 
40 
20 
N-295 
P3D4 
N-296 
,01  ,1  1  10  100 
Antibody dilution  (xlO0) 
Figure 8. Effect of anti-Fn antibodies on TS2/16-treated Ramos cell 
adhesion to the 80-kD fragment. The indicated dilutions of N-295 
(anti-RGD), P3D4 (anti-Hep ID, or N-296 (anti-Fib II site, control) 
were added to 80-kD fragment coated wells (38#g/ml) and in- 
cubated for 30 min at room temperature. Cells previously incubated 
with rnAb TS2/16 (15 min at 37°C) were added and attachment was 
quantitated as described. Values are expressed as percentage rela- 
tive to the number of cells on control wells (no inhibitor) and are 
the average of two different experiments. 
tively bound to the 80-kD fragment and showed low constitu- 
tive binding  to laminin  and  collagen.  Preincubation with 
mAb TS2/16 effectively increased A375 cell adhesion to all 
three substrata (Fig. 9) in agreement with previous reports 
(1,  2).  This effect was not due to cross-linking of cells to 
ECM proteins via the TS2/16 antibody because in control ex- 
periments mAb TS2/16 did not bind to either Fn, laminin, 
or collagen (results not shown). Increased adhesion of A375 
cells to ECM proteins was rather due to the upregulation of 
et5E1, ot2/~l, and ot6E1 integrins which are receptors for the 
80-kD Fn fragment, collagen, and laminin, respectively (1, 
2, 6). As expected, RPMI 8866 and JY cells, which lack/~1, 
did not bind to laminin or collagen in response to incubation 
with mAb TS2/16 (not shown). 
To determine whether the effect of mAb TS2/16 on ot4E1 
was also observed on other integrins such as ot5E1, K562 
cells were incubated with this rnAb and tested for adhesion 
to the 38-kD fragment. K562 ceils do not express ot4E1 (Ta- 
ble I) and consequently they do not bind to the 38-kD frag- 
ment constitutively, mAb TS2/16 did not induce adhesion of 
K562 cells to the 38-kD fragment although this mAb effec- 
tively enhanced their constitutive binding to the 80-kD frag- 
ment via ~5E1  (results not shown).  Thus the capacity to 
recognize new ligands upon activation via E1 may be an in- 
trinsic property of the ot4~l  integrin. 
nition of other extracellular matrix (ECM) proteins not pre- 
viously known to interact with ct4fll. To this purpose, we per- 
formed cell attachment assays using collagen and laminin as 
substrata. These two proteins are known ligands for other E1 
integrins including ct2E1, a3E1, and o~6E1 (20). As shown 
in Fig. 9, incubation of Ramos cells with mAb TS2/16 did 
not result in adhesion to either laminin or collagen. Because 
ot4E1 is the main integrin expressed on Ramos cells (Table 
I) these results indicate that mAb TS2/16 does not induce 
ot4Bl recognition of laminin or collagen. To confirm that it 
was enough substrata on the plates to support cell attachment 
we used the melanoma cell line A375 as control. A375 cells 
express several E1 integrins (Table I) including the laminin 
receptor ct6B1 (1). As shown in Fig. 9, A375 cells constitu- 
Figure 9. Effect ofmAb TS2/16 on cell adhesion to laminin and col- 
lagen type I.  Ramos or control A375 melanoma cells  were in- 
cubated with mAb TS2/16 prior to adding to 80 kD (38 #g/ml), 
laminin (LM, 150 #g/ml),  or type I collagen (COL,  150 ttg/ml) 
coated wells. After 30 min at 37°C attached cells were quantitated 
as described.  Values on the ordinate represent the number of at- 
tached cells relative to the total cell input (5  ×  liT/well) and are 
the means of two different experiments. 
Discussion 
The major conclusions of this report are: (a) ot5El-negative 
human B lymphoid cells, which do not bind constitutively 
to the 80-kD fragment of Fn, acquire the capacity to attach 
to this fragment upon incubation with anti-~ mAb TS2/16; 
(b) the B lymphoid cell receptor that interacts with the 80-kD 
fragment is the oL4E1 integrin; (c) the RGDS sequence is a 
ligand for TS2/16-activated o~4E1 integrin, this indicates that 
the conformational change induced on ot4/~l by mAb TS2/16 
results in the ability to recognize RGD; and (d) a4E1 on B 
lymphoid cells can be induced to recognize novel ligands in 
Fn but not in laminin or type I collagen. 
Our previous work has definitely established that some B 
lymphoid cells do not express the ot5E1 integrin and are un- 
able to attach to the 80-kD fragment containing the RGD site 
(16).  In the present study we show that incubation of the 
ct5El-negative B cell lines Ramos and Daudi with anti-/~l 
mAb TS2/16 results in an efficient and specific attachment 
to the 80-kD fragment. Our results clearly show that adhe- 
sion of B cells to the 80-kD fragment is mediated by the 
ot4E1 integrin. This was demonstrated by the ability of mAbs 
anti-or4 and the synthetic peptides CS-1 and IDAPS to inhibit 
cell attachment to  the  80-kD  fragment.  Interestingly, the 
GRGDSPC synthetic peptide was  also a good inhibitor of 
TS2/16-treated a4/~l function. We have conclusively shown 
in previous work that the interaction of  ot4~l with its ligands, 
the 38- and 58-kD Fn fragments, is not affected by RGD- 
containing peptides  (12,  15,  16,  52).  Consistent with this 
Ramos  (untreated or treated with a  control mAb) cell at- 
tachment to the  38-kD  fragment was  not affected by the 
GRGDSPC peptide (this report, Fig.  7).  As  shown in the 
present studies, the RGD sequence not only inhibited TS2/ 
16-treated 0~4/31 function in soluble form but was also the 
primary site that mediated attachment to the 80-kD frag- 
ment, as suggested by the good inhibition attained by N-295 
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kD which may act synergistically with RGD cannot be com- 
pletely disregarded. 
In a previous report (34) Mould et al., showed that oL4/31- 
mediated spreading of melanoma ceils can be inhibited by 
RGD synthetic peptides and that these peptides may elute the 
ot4/31 integrin complex from a CS-I affinity column. In con- 
trust with these findings, we did not observe ot4/31 recogni- 
tion of RGD-synthetic peptides unless previous incubation of 
B cells with mAb TS2/16. Although we cannot explain this 
discrepancy with the available data, it should be considered 
that a direct comparison between the work by Mould et al., 
and ours is difficult because of the different cell types and 
phenomena studied (spreading versus adhesion).  Alterna- 
tively, it is possible that the melanoma cells used in reference 
34 bear a constitutively activated form of ct4/31 sensitive to 
RGD-containing peptides. 
Several studies have shown that certain anti-/31 mAbs en- 
hance the function of some/31 integrins by inducing a confor- 
mational change which results in an activated form of the 
receptor with higher avidity/affinity  for its ligands (1, 27, 49, 
53). The activated form of the receptor may display broader 
ligand specificity than the resting form. For example, ot2/31 
is a collagen receptor on platelets and fibroblasts and a colla- 
gen and laminin receptor on other cell types (8, 23, 29). A 
recent report has shown that, on the same cell, mAb TS2/16 
can convert the partly active form of ot2/31 which recog- 
nizes only collagen to a  fully active form that also binds 
laminin (6). 
We and others have recently shown that o~4/31 also exists 
in several states of activation among different hemopoietic 
cells. Monocytic cells and PBL bear a partly active form of 
ot4/31 which recognizes CS-1 but not Hep II; mAb TS2/16 
converted ot4/31 to a more active form (constitutively  present 
on cultured lymphoid cells) able to recognize both ligands 
in Fn (44).  In another study that compares the binding to 
CS-1 and vascular cell adhesion molecule-1  (VCAM-1), the 
less active form of u4/31 bound only VCAM-1 while the 
TS2/16-activated form bound VCAM-1 and CS-1 (30).  The 
phorbol ester PMA can also activate o~4/31 on U937 ceils or 
PBL (44). It is interesting that in the present studies PMA 
did not induce Ramos or Daudi cell attachment to the 80-kD 
fragment. PMA did not enhance either the constitutive bind- 
ing of these cells to the 38-kD fragment thus suggesting that 
the ot4/31 form present on Ramos and Daudi cells cannot be 
further activated by phorbol esters. A different regulation of 
ot4/31 function by anti-/31 mAbs and Ca  2÷ has already been 
observed (30). It has also been reported that PMA has no (or 
minimal) effect on the binding of c~2/31 to collagen or lami- 
nin while mAb TS2/16 was highly stimulatory (6).  The fact 
that mAb TS2/16  can also activate solubilized/31 integrins 
(2, 6) is in accordance with the lack of requirement for an 
intraceilular activation pathway. These observations support 
the existence of distinct mechanistic ways of regulating inte- 
grin function. Because PMA does increase c~4/31 function on 
some cells, it is possible that the sensitivity to a particular 
stimulus is determined by the activation state of the integrin 
or by the cell type or both. 
These previous studies have analyzed the effect of anti-/31 
mAbs or PMA on the interaction of tx4/31 with its already 
identified ligands (CS-1, Hep II, and VCAM-1). Similarly, 
although the study by Chart and Hemler (6) clearly shows 
changes in specificity according to the activation state of 
o~2/31, there are cell populations that bind laminin or/and col- 
lagen constitutively. The novelty of the present results is that 
mAb TS2/16 induces binding to a region of Fn (80-kD frag- 
ment) not previously identified as an ot4/31 ligand. In fact, 
the 80-kD fragment is a well described ligand for the ot5/31 
integrin and we have extensively documented that the consti- 
tutive function of ot4/31 on leukocytes is RGD independent 
(12,  15, 16, 52). The activated form of o~4/31 described here 
not only binds CS-1 and Hep II with high avidity, but also 
recognizes RGD. 
Although in general a single integrin binds several ligands, 
ot4/31 can bind multiple and apparently quite distinct se- 
quences within the same or different molecules. Within Fn 
the minimal sequences shown to be ot4/31 ligands are LDV 
(contained in  CS-1 [26, 53]),  REDV  (contained in  CS-5 
[34]),  and IDAPS (contained in HI [35]).  It has been pro- 
posed that the common aspartate residue on these sequences 
is important for o~4/31 recognition (35).  While this may be 
true,  it is clear that other sequences may also be specific 
oL4/31 ligands. There is indirect evidence that the FNC/H I 
(YIKPGSPPREVVPRPRPGV) and FNC/H II (KNNQKS- 
EPLIGRKKT) peptides derived from the Hep II Fn domain 
(31) may also interact with ot4/31 (21). All these sequences 
(CS1, CS5, HI, FNC/H I, and FNC/H II) are located in close 
proximity within the type M-14 repeat and the contiguous 
MCS region of Fn (see Fig. 1). Besides Fn, ot4/31 is also the 
receptor for VCAM-1 (9), the bacterial protein invasin (10), 
and thrombospondin (55).  Although the cell-binding site(s) 
for some of these proteins has not been identified, it seems 
clear that the interaction of ct4/31 with VCAM-1 does not in- 
volve the LDV motif present on this protein (37, 51). 
The present results show that the conformational change 
induced in ot4/31 through the ~  subunit allows recognition 
of the Fn RGD sequence which is located in repeat M-10 and 
thus distant from the previously described a4/31 ligands. In- 
terestingly, Koivunen et al. (24, 25), using a phage display 
library, have recently identified several cyclic synthetic pep- 
tides which bind the o~5/31 integrin and do not contain the 
RGD motif. One of these peptides corresponds to the se- 
quence STSDVGG which is homologous to the TVSDVPR 
sequence present in repeat M-10 of Fn. As noticed in that 
report,  there  is  also  some  degree  of  homology  with 
EILDVPST, a sequence present in CS-1 which we and others 
have shown to be a high affinity ligand for ot4/31 (16, 18, 33, 
52). Although these authors did not show direct interaction 
of o~5/31 with either of the two homologous sequences pres- 
ent in Fn, their work suggests that a5/31 has the potential to 
recognize other ligands in Fn besides  RGD.  Our present 
results are in agreement with a certain degree of overlapping 
in ligand recognition by the 0t4/31 and ot5/31 integrins. This 
is also supported by another report that shows that a synthetic 
cyclic peptide, distinct from RGD,  can inhibit the function 
of et4/31 and o~5/31 integrins (36).  While peptide cyclation 
may provide an optimal ligand conformation for high affinity 
interactions with either ot4/31 or o~5/31, it is clear from our 
present study that mAb TS2/16 does not induce ot5/31 bind- 
ing to the CS-1 sequence of Fn.  Therefore the ability to 
recognize new ligands upon conformational activation may 
be intrinsic to the ot4/31 structure. 
The present report therefore describes a  novel role for 
ct4/31 as a receptor for the RGD site in Fn. Because t~5/31 
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study the contribution of c~4B1 to cell adhesion to the 80-kD 
Fn fragment when both integrins are expressed together. In 
experiments  not shown,  we tested whether  anti-or4  mAbs 
could partially  inhibit the binding of TS2/16-treated  U937 
ceils to the 80-kD fragment. However, because mAb TS2/16 
also effectively upregulates the adhesion mediated by ot5B1 
(1, 2, and this study), we could not detect any inhibition with 
mAbs anti-or4.  It is possible that when c~5B1 and ot4~l are 
present  together,  o~5~1 function  predominates  over 0~4~/1 
function in mediating adhesion to Fn. In support of this, the 
80-kD fragment or the GRGD synthetic peptide completely 
inhibit U937 cell adhesion to Fn while the 38-kD fragment 
or the CS-1  peptide produce partial  or no inhibition  (12). 
These results do not rule out a cooperation of both receptors 
for an efficient attachment to Fn as we have previously pro- 
posed for T lymphoid cells (15).  The results reported here 
are obviously important for cells which express ~4~/1 as the 
major surface integrin.  These include B cells (16, 47), some 
B cell progenitors (43), and probably some tumor cells. Fur- 
thermore,  there  are  reports  showing different interactions 
with Fn during pre-B cell development (3, 50). On ceils that 
express c¢5~1 besides o~4#1, properly activated a4~l  may 
serve to cooperate with c~5~1 or to functionally replace it 
when ot5~l  is already engaged. 
It is now well documented that integrins undergo transi- 
tions among different states of activation (20) and that these 
transitions  are  induced  by  several  agents  including  some 
mAbs as shown in the present report. The fact that the vari- 
ous  integrin  activation  forms  are  also  found  in  vivo,  as 
clearly shown for o~4~1 for example (28), suggests that ac- 
tivating anti-/51 mAbs (TS2/16 and others) are mimicking the 
effect of physiological ligands not yet identified. On the other 
hand, the multiplicity of sequences recognized by a4/31 must 
have physiological relevance.  For example, it may serve to 
drive synergistic interactions with the receptor resulting in 
high affinity binding.  Such synergy has already been shown 
for a5/31  interaction  with the RGD sequence in Fn  (56). 
Similarly,  activation  of the  platelet  integrin  cd/b/~3  with 
thrombin  results in recognition of an additional  Fn region 
(besides RGD) comprising part of homology repeats III-9 
and HI-10 (4, see Fig.  1). An interesting possibility is that 
some of the sequences that interact with ot4/~1 may regulate 
o~4/31 binding to other ligands, as already shown for otIlb/33 
(7). The ot4/~l ligands described so far,  including the RGD 
site identified in this report, apparently bind to identical or 
overlapping sites on t~4/31 because they are cross-inhibitory. 
However,  it  seems  possible  that  other  not  yet  identified 
ligands bind a4/31 with low affinity or at a different site, and 
upregulate rather than inhibit the function of ct4/31. In sup- 
port of this is the fact that two Fn sequences shown to interact 
with ~4/~1, FNC/H I, and FNC/H II, do not (or slightly) in- 
terfere with t~4/31 adhesive function (21, 31). The phage dis- 
play library approach used for identification of ligands for 
ot5/~l (24, 25) may he a useful one to identify new potential 
ligands  for ct4/~l.  This  would also open the possibility of 
using these modulatory sequences for therapeutic purposes. 
Moreover, because the avidity of a4/~1 for CS-1, Hep II, and 
RGD is different,  binding  to each of these sites may have 
different cellular consequences. Another implication of the 
present study is that physiologically stimulated ~4/31  may 
play an important role for the recruitment of lymphocytes at 
inflammatory sites and tissues where Fn fragments contain- 
ing CS-1,  Hep II,  or/and RGD are produced.  While these 
possibilities require further study, our results highlight the 
role of c¢4B1 as a flexible receptor able to recognize multiple 
ligands and support the importance of the extracellular ma- 
trix,  particularly  Fn,  on  lymphocyte  development  and 
function. 
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